Cellectis to release Q1 2026 financial results on May 11 after US market close

Cellectis, a clinical-stage biotech company specializing in gene-editing therapies, announced it will report its financial results for the first quarter of 2026 on May 11, after the US market closes. The company, known for its allogeneic CAR T-cell therapies for cancer and gene therapy platforms, will publish the results on its website but will not hold a conference call. Investors can direct questions to the company's investor relations team. This update is important as it provides insight into the company's financial health and progress in its pioneering gene-editing treatments.